Načítá se...

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

Targeting specific molecular alterations in glioblastoma (GBM) might more effectively kill tumor cells and increase survival. Vandetanib inhibits epidermal growth factor receptor and vascular endothelial growth factor receptor 2. Sirolimus inhibits mammalian target of rapamycin (mTOR), a member the...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	J Neurooncol
Hlavní autoři:	Chheda, Milan G., Wen, Patrick Y., Hochberg, Fred H., Chi, Andrew S., Drappatz, Jan, Eichler, April F., Yang, Daniel, Beroukhim, Rameen, Norden, Andrew D., Gerstner, Elizabeth R., Betensky, Rebecca A., Batchelor, Tracy T.
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	2014
Témata:	Article
On-line přístup:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4324090/ https://ncbi.nlm.nih.gov/pubmed/25503302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1680-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo otaguje tento záznam!

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

Podobné jednotky